126 related articles for article (PubMed ID: 2380017)
1. A phase I and pharmacokinetic study of intravenous vinzolidine.
Taylor CW; Salmon SE; Satterlee WG; Robertone AB; McCloskey TM; Holdsworth MT; Plezia PM; Alberts DS
Invest New Drugs; 1990; 8 Suppl 1():S51-7. PubMed ID: 2380017
[TBL] [Abstract][Full Text] [Related]
2. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.
Takasugi BJ; Robertone AB; Salmon SE; Jones SE; Alberts DS
Invest New Drugs; 1984; 2(4):387-90. PubMed ID: 6096287
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.
Budman DR; Kreis W; Behr J; Schulman P; Lichtman S; Allen SL; Weiselberg L; Satterlee WG; Nelson RL; Vinciguerra V
Invest New Drugs; 1990 Aug; 8(3):269-74. PubMed ID: 2272767
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
Takasugi BJ; Jones SE; Robertone AB
Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of vinzolidine.
Budman DR; Schulman P; Marks M; Vinciguerra V; Weiselberg L; Kreis W; Degnan TJ
Cancer Treat Rep; 1984; 68(7-8):979-82. PubMed ID: 6744350
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
Kreis W; Budman DR; Freeman J; Bergstrom RF; Nelson RL
Cancer Chemother Pharmacol; 1990; 26(6):419-22. PubMed ID: 2225313
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
Adenis A; Pion JM; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
Cancer Chemother Pharmacol; 1995; 35(6):527-8. PubMed ID: 7882462
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of vindesine in patients with advanced cancer.
Currie VE; Wong PP; Krakoff IH; Young CW
Cancer Treat Rep; 1978 Sep; 62(9):1333-6. PubMed ID: 356986
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
13. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum.
Sarna G; Mitsuyasu R; Figlin R; Ambersley J; Groopman J
Cancer Chemother Pharmacol; 1985; 14(1):12-4. PubMed ID: 3965155
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
18. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of vintriptol, a tryptophan ester of vinblastine.
Oosterkamp HM; Vlasveld LT; Wanders J; Beijnen JH; van Tellingen O; Dubbelman AC; Simonetti GP; Franklin HR; Vermorken JB; Ten Bokkel Huinink WW
Eur J Cancer; 1991; 27(10):1222-6. PubMed ID: 1835590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
